Personalis, Inc.
PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tiā¦ read more
Healthcare
Diagnostics & Research
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$18.38
Price+8.89%
$1.50
1Y
Price
Market Cap
$1.962b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-178.4%
EBITDA Margin-194.1%
Net Profit Margin-165.9%
Free Cash Flow Margin-178.4%
EBITDA Margin-194.1%
Net Profit Margin-165.9%
Free Cash Flow MarginRevenue
$64.515m
-
1y CAGR-28.3%
3y CAGR-18.0%
5y CAGREarnings
-$95.552m
-17.6%
1y CAGR+2.5%
3y CAGR+3.0%
5y CAGREPS
-$1.02
-12.1%
1y CAGR+20.2%
3y CAGR+17.5%
5y CAGRBook Value
$254.765m
$325.395m
Assets$70.630m
Liabilities$38.781m
DebtDebt to Assets
11.9%
-0.4x
Debt to EBITDAFree Cash Flow
-$84.648m
-6.5%
1y CAGR-15.4%
3y CAGR-0.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company